Picture of Takeda Pharmaceutical Co logo

TAK Takeda Pharmaceutical Co News Story

0.000.00%
us flag iconLast trade - 00:00
HealthcareConservativeLarge CapNeutral

REG - JPMorgan Sec.Plc Takeda Pharma.Co.Ltd - Form 8.5 (EPT/RI)- Takeda Pharmaceutical Co Ltd





 




RNS Number : 3822M
JPMorgan Securities Plc
07 January 2019
 

FORM 8.5 (EPT/RI)

 

PUBLIC DEALING DISCLOSURE BY AN EXEMPT PRINCIPAL TRADER WITH RECOGNISED INTERMEDIARY STATUS DEALING IN A CLIENT-SERVING CAPACITY

Rule 8.5 of the Takeover Code (the "Code")

 

1.         KEY INFORMATION

 

(a) Name of exempt principal trader:

J.P. Morgan Securities Plc

(b) Name of offeror/offeree in relation to whose relevant securities this form relates:

     Use a separate form for each offeror/offeree

Takeda Pharmaceutical Company Limited

(c) Name of the party to the offer with which exempt principal trader is connected:

Joint Financial Adviser to Takeda Pharmaceutical Company Limited

(d) Date dealing undertaken:

04 January 2019

(e) In addition to the company in 1(b) above, is the exempt principal trader making disclosures in respect of any other party to this offer?

     If it is a cash offer or possible cash offer, state "N/A"

Yes, Shire plc

 

 

2.         DEALINGS BY THE EXEMPT PRINCIPAL TRADER

 

Where there have been dealings in more than one class of relevant securities of the offeror or offeree named in 1(b), copy table 2(a), (b), (c) or (d) (as appropriate) for each additional class of relevant security dealt in.

 

The currency of all prices and other monetary amounts should be stated.

 

(a)        Purchases and sales

 

Class of relevant security

Purchases/ sales

 

Total number of securities

Highest price per unit paid/received

(JPY)

Lowest price per unit paid/received

(JPY)

Ordinary Shares

 

Purchases

 

Sales

444,454

 

224,703

3,737.3917

 

3,737.3917

3,620.0000

 

3,620.0000

 

(b)        Cash-settled derivative transactions

 

Class of relevant security

Product description

e.g. CFD

Nature of dealing

e.g. opening/closing a long/short position, increasing/reducing a long/short position

Number of reference securities

Price per unit

(JPY)

 

 

Ordinary Shares

 

Equity Swaps

Long

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Short

3,100

46,400

100

3,400

100

1,800

1,500

103,100

3,700

100

1,300

16,200

200

15,000

10,000

15,000

300

4,200

900

43,900

9,200

200

200

200

7,600

400

4,200

7,600

100

 

2,300

800

600

8,200

100

103,100

1,800

114,100

200

2,900

2,500

200

300

9,000

13,100

25,100

400

400

4,900

9,900

100

3,620.0000

3,677.2586

3,684.0000

3,688.3235

3,689.5000

3,690.0000

3,701.2187

3,702.4534

3,705.1351

3,708.0000

3,711.7692

3,712.3148

3,715.0000

3,717.8026

3,723.0200

3,725.1687

3,727.2667

3,727.6429

3,730.2222

3,730.3144

3,731.8243

3,732.5000

3,737.1263

3,746.4500

3,750.8158

3,751.2500

3,753.2381

3,754.7895

3,761.0000

 

3,620.3622

3,620.7238

3,659.5000

3,687.5244

3,688.2028

3,702.4534

3,707.1667

3,708.0173

3,710.0000

3,710.0345

3,714.6400

3,715.0000

3,722.0000

3,724.2000

3,724.2430

3,727.3704

3,736.3706

3,745.0000

3,750.0000

3,751.4040

3,760.0000

 

(c)        Stock-settled derivative transactions (including options)

 

(i)         Writing, selling, purchasing or varying

 

Class of relevant security

Product description e.g. call option

Writing, purchasing, selling, varying etc.

Number of securities to which option relates

Exercise price per unit

(JPY)

Type

e.g. American, European etc.

Expiry date

Option money paid/ received per unit

(JPY)









 

(ii)        Exercise

 

Class of relevant security

Product description

e.g. call option

Exercising/ exercised against

Number of securities

Exercise price per unit

 





 

 

 

(d)        Other dealings (including subscribing for new securities)

 

Class of relevant security

Nature of dealing

e.g. subscription, conversion

Details

Price per unit (if applicable)


 

 



 

3.         OTHER INFORMATION

 

(a)        Indemnity and other dealing arrangements

 

Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the exempt principal trader making the disclosure and any party to the offer or any person acting in concert with a party to the offer:

Irrevocable commitments and letters of intent should not be included.  If there are no such agreements, arrangements or understandings, state "none"

None

 

 

 

(b)        Agreements, arrangements or understandings relating to options or derivatives

 

Details of any agreement, arrangement or understanding, formal or informal, between the exempt principal trader making the disclosure and any other person relating to:

(i)  the voting rights of any relevant securities under any option; or

(ii) the voting rights or future acquisition or disposal of any relevant securities to which any derivative is referenced:

If there are no such agreements, arrangements or understandings, state "none"

None

 

 

 

Date of disclosure:

07 January 2019

Contact name:

Alwyn Basch

Telephone number:

020 7742 7407

 

Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service. The Panel's Market Surveillance Unit is available for consultation in relation to the Code's dealing disclosure requirements on +44 (0)20 7638 0129.

 

The Code can be viewed on the Panel's website at www.thetakeoverpanel.org.uk.


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
FERSSSFFWFUSESF

Recent news on Takeda Pharmaceutical Co

See all news